Depo Provera Tumour Class Action

Rice Harbut Elliott LLP has filed a proposed class action lawsuit on behalf of Canadians who developed brain and spinal tumours or lesions – called meningiomas – after receiving the Depo-Provera injection, which is used as birth control and to treat endometriosis.

Class Action Details
Documents and Updates

Class Action Details

RHE seeks to recover compensation for Canadians affected with brain and spinal tumours or lesions known as meningiomas after taking Depo-Provera.

Depo-Provera Brain Tumour Risks:

The active ingredient in Depo-Provera, medroxyprogesterone acetate, has been linked to an increased risk of developing meningiomas. A large French study was published in March 2024 finding that reproductive-aged women who used medroxyprogesterone acetate had a 5.55-fold increased risk of meningiomas. This same study also found that women taking other types of contraceptives, including oral birth control pills, were not at an increased risk.

Meningiomas are typically benign tumours that develop in tissues surrounding the brain and spinal cord. Since they can grow and put pressure on adjacent brain tissue and structures, they often require surgical or radiation treatment with the potential to cause brain injury.

The lawsuit alleges that the defendants, Pfizer Inc. and its subsidiaries, failed to ensure that Depo-Provera was safe for its ordinary use and provided no warning to consumers of this possibly life-threatening tumours, despite the company knowing about the risks for some time.

Women Diagnosed with Meningiomas After Using Depo-Provera

If you or a member of your family has suffered injuries or complications from Depo-Provera, our class action team is available to try to assist you in seeking compensation.

Complete the form below to subscribe to our database and receive all updates and notices regarding this class action.

Documents and Updates

Please see the Notice of Civil Claim for more information about the Class Action.

This litigation is still in its early stages. The court will decide at a later date if the case will proceed as a class action.

Note: You are not obliged to fill in this form to participate in this class action. If you choose to do so, you are not retaining RHE LLP to act on your behalf. Providing the information requested does not make you a client of RHE LLP. All information submitted will be treated as confidential and will only be released as required by law or as you may consent.

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing reception@rhelaw.com.

Class Action Form

Contact Information

First and Last Name* *

Email* *

Phone* *

Address* *

City/Town* *

Province or Territory* *

Postal Code* *

Date of Birth* *

Personal Health Number* *

Date of prescription *

Duration of prescription

Date of diagnosis

Other Coments

Consent* *

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that I can unsubscribe to these emails at any time. I understand that some of the personal information that I provide may be stored or processed outside of British Columbia and/or Canada, on a US server, and will be kept confidential, subject to the potential that a foreign state may seek to access the data for “lawful access” purposes. If you have any questions about RHE’s policies and practices regarding service providers outside Canada, or about the collection, use, disclosure or storage of personal information by the service providers outside Canada, please contact reception@rhelaw.com.

Custom Captcha *